Cite
HARVARD Citation
Dubourg, J. et al. (2021). Efficacy and safety of imeglimin in Japanese patients with type 2 diabetes: A 24‐week, randomized, double‐blind, placebo‐controlled, dose‐ranging phase 2b trial. Diabetes, obesity & metabolism. 23 (3), pp. 800-810. [Online].